Despite the fact that BCMA- or CD22-targeted CAR T cells also exhibit tremendous anti-tumor activity in multiple myeloma and acute lymphoblastic leukemia (31, 71), all these target antigens are highly restricted to the B cell lineage. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.